Medifast (MED) Projected to Post Earnings on Tuesday

Medifast (NYSE:MED) is anticipated to post its Q4 2025 results after the market closes on Tuesday, February 17th. Analysts expect Medifast to post earnings of ($0.80) per share and revenue of $71.40 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, February 17, 2026 at 4:30 PM ET.

Medifast Trading Down 0.3%

Shares of NYSE MED opened at $10.78 on Monday. The stock has a fifty day simple moving average of $11.37 and a two-hundred day simple moving average of $12.36. Medifast has a 1-year low of $10.10 and a 1-year high of $16.66. The firm has a market cap of $118.42 million, a price-to-earnings ratio of 1,077.50 and a beta of 0.53.

Hedge Funds Weigh In On Medifast

Several hedge funds have recently bought and sold shares of MED. Lido Advisors LLC purchased a new stake in Medifast in the 3rd quarter worth approximately $4,521,000. Charles Schwab Investment Management Inc. raised its position in shares of Medifast by 30.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 776,829 shares of the specialty retailer’s stock worth $8,297,000 after buying an additional 181,618 shares in the last quarter. Bank of America Corp DE raised its position in shares of Medifast by 37.4% in the second quarter. Bank of America Corp DE now owns 396,369 shares of the specialty retailer’s stock worth $5,569,000 after buying an additional 107,854 shares in the last quarter. Victory Capital Management Inc. bought a new stake in Medifast during the third quarter valued at $867,000. Finally, Bridgeway Capital Management LLC grew its position in Medifast by 104.5% during the third quarter. Bridgeway Capital Management LLC now owns 118,477 shares of the specialty retailer’s stock worth $1,620,000 after buying an additional 60,533 shares in the last quarter. Hedge funds and other institutional investors own 95.51% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on MED shares. Wall Street Zen upgraded Medifast from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Weiss Ratings restated a “sell (d)” rating on shares of Medifast in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Reduce” and an average price target of $16.50.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.